Renaissance Technologies’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Renaissance Technologies’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-89,300	Closed	-$118K	–	4678
2022 Q1	$118K	Buy	+89,300	New	+$145K	﹤0.01%	3766
2021 Q4	–	Sell	-100,566	Closed	-$313K	–	4337
2021 Q3	$313K	Buy	+100,566	New	+$336K	﹤0.01%	3066
2021 Q1	–	Sell	-83,400	Closed	-$280K	–	3848
2020 Q4	$280K	Buy	+83,400	New	+$299K	﹤0.01%	3057
2020 Q3	–	Sell	-131,500	Closed	-$605K	–	3797
2020 Q2	$605K	Sell	131,500 -31,700	-19%	-$140K	﹤0.01%	2801
2020 Q1	$540K	Buy	+163,200	New	+$747K	﹤0.01%	2726
2019 Q4	–	Sell	-56,200	Closed	-$234K	–	3818
2019 Q3	$234K	Buy	+56,200	New	+$448K	﹤0.01%	3101

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Renaissance Technologies's PHAS Position: Q2 2022 in Review

Renaissance Technologies sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2022, closing a stake of 89,300 shares — an estimated $118K sold.

Renaissance Technologies first reported a position in PHAS in Q3 2019 and held it in 6 quarters. The position peaked at $605K in Q2 2020. 49 funds tracked by Wall St. Rank hold PHAS as of Q2 2022.

Renaissance Technologies reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Renaissance Technologies sold 89,300 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $118K.
Renaissance Technologies first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 6 quarters.
Renaissance Technologies's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $605K in Q2 2020.
49 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Renaissance Technologies's 13F filing for Q2 2022, filed 12 Aug 2022.